{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-11-08T17:39:00.465Z","profile":{"slug":"pemvidutide","name":"Pemvidutide","aliases":[],"category":"GLP-1/glucagon receptor agonist"},"synthesis":{"mechanism":"Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis and related metabolic outcomes. Liver histology, noninvasive markers, weight, and cardiovascular risk factors are distinct endpoints.","evidence":"WPF’s atlas includes reports and abstracts from the phase 2b IMPACT study and a meta-analysis of randomized trials. Conference abstracts and top-line reports can flag emerging results, but require comparison with complete methods and peer-reviewed outcome data before firm conclusions.","safety":"A change in a surrogate marker or exploratory analysis does not by itself establish clinical benefit, durability, or an approved indication.","observationalBoundary":"WPF's separate observational archive may include contributor reports concerning pemvidutide, investigated for liver-, weight-, and cardiovascular-risk-related outcomes. As with every entry in that archive, these de-identified reports can suggest questions but cannot establish causation, efficacy, comparative safety, or event frequency, and reports concerning different outcome domains should be interpreted separately.","openQuestions":"What do full controlled trial reports show for predefined liver outcomes and harms? How do noninvasive tests align with histology? Which effects persist beyond the reported follow-up?"},"completion":{"version":"wpf-profile-v1.1","verifiedSourceCount":24,"evidenceDepth":"limited_evidence","complete":false,"checks":[{"key":"overview","passed":true,"actual":256,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":285,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":140,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":420,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":183,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":24,"required":1,"severity":"blocking"},{"key":"evidence_depth_target","passed":false,"actual":24,"required":25,"severity":"warning"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["evidence_depth_target","reviewed_sources","claims"]},"chemistry":{"id":"fef3f313-8c7d-47f8-9e07-13cebda3960e","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","molecularFormula":null,"molecularWeight":null,"aminoAcidSequence":"His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Ala-Ala-Lys-Glu-Phe-Ile-Gln-Trp-Leu-Leu-Gln-Thr-NH2","smiles":null,"inchi":null,"inchikey":null,"structureImageUrl":null,"createdAt":"2026-09-23T02:36:54.177Z","updatedAt":"2026-09-23T02:36:54.177Z"},"evidence":[{"id":"6faf931b-d303-4c27-9a63-aaea031bb637","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"228-OR: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids","sourceUrl":"https://doi.org/10.2337/db24-228-or","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.2337/db24-228-or","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.2337/db24-228-or","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:02.949Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5ugc006zfqe3r9bsqdc2","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.2337/db24-228-or","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.2337/db24-228-or","pmid":null,"title":"228-OR: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids","locator":"https://doi.org/10.2337/db24-228-or","provider":"crossref","retrievedAt":"2026-09-27T01:16:02.949Z","rawPayloadHash":"fdfaa9d48cc471c2e0816a4a8e310278522341f7f7514e20d2e13876f39002b0"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:16:02.949Z","sourceUrl":"https://doi.org/10.2337/db24-228-or","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:10.671Z","updatedAt":"2026-09-27T02:32:10.671Z"},{"id":"53eb521a-a35e-4d75-aea3-3f56b8c3f62f","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"228-OR: Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight","sourceUrl":"https://doi.org/10.2337/db25-228-or","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.2337/db25-228-or","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.2337/db25-228-or","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:15:58.951Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5s50006rfqe3324uxe4i","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.2337/db25-228-or","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.2337/db25-228-or","pmid":null,"title":"228-OR: Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight","locator":"https://doi.org/10.2337/db25-228-or","provider":"crossref","retrievedAt":"2026-09-27T01:15:58.951Z","rawPayloadHash":"4e7dbf9711e8b5db85aefb859eb422b2c45c03a9aeb84d822003fbb867164b7f"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:15:58.951Z","sourceUrl":"https://doi.org/10.2337/db25-228-or","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:10.957Z","updatedAt":"2026-09-27T02:32:10.957Z"},{"id":"50d23c8c-8641-471a-925b-70d55af30321","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial","sourceUrl":"https://doi.org/10.2337/db24-262-or","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.2337/db24-262-or","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.2337/db24-262-or","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:01.910Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5tvl006xfqe3zjvk7iv7","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.2337/db24-262-or","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.2337/db24-262-or","pmid":null,"title":"262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial","locator":"https://doi.org/10.2337/db24-262-or","provider":"crossref","retrievedAt":"2026-09-27T01:16:01.909Z","rawPayloadHash":"e7f2155a41ee0b659dcdd78c2104fb7042cb9177ba18ab5c6c4a0daadcb73923"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:16:01.910Z","sourceUrl":"https://doi.org/10.2337/db24-262-or","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.390Z","updatedAt":"2026-09-27T02:32:11.390Z"},{"id":"86457df2-fd09-400c-b05b-8a9624688213","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity","sourceUrl":"https://doi.org/10.2337/db22-334-or","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.2337/db22-334-or","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.2337/db22-334-or","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:04.441Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5vb70072fqe38qgor0tc","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.2337/db22-334-or","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.2337/db22-334-or","pmid":null,"title":"334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity","locator":"https://doi.org/10.2337/db22-334-or","provider":"crossref","retrievedAt":"2026-09-27T01:16:04.440Z","rawPayloadHash":"dba9e28fa035ac24b4096e484ce74295925d61864f7115f7d8b8e2f87424b92f"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:16:04.441Z","sourceUrl":"https://doi.org/10.2337/db22-334-or","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.673Z","updatedAt":"2026-09-27T02:32:11.673Z"},{"id":"1132cdba-1775-4ed9-b3f1-535da8fc28a2","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"748-P: Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide","sourceUrl":"https://doi.org/10.2337/db25-748-p","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.2337/db25-748-p","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.2337/db25-748-p","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:15:58.467Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5ra4006ofqe3ef31arqd","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.2337/db25-748-p","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.2337/db25-748-p","pmid":null,"title":"748-P: Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide","locator":"https://doi.org/10.2337/db25-748-p","provider":"crossref","retrievedAt":"2026-09-27T01:15:58.467Z","rawPayloadHash":"4b77fa10f9da0bd2416d15842dedd3d3244ca0cf467c8aca08d64f0dda455fa0"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:15:58.467Z","sourceUrl":"https://doi.org/10.2337/db25-748-p","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:10.887Z","updatedAt":"2026-09-27T02:32:10.887Z"},{"id":"421cf697-2b34-46e5-be3d-bd95d5e27ad8","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"749-P: Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment","sourceUrl":"https://doi.org/10.2337/db25-749-p","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.2337/db25-749-p","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.2337/db25-749-p","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:00.439Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5t0m006ufqe34lui3hxz","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.2337/db25-749-p","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.2337/db25-749-p","pmid":null,"title":"749-P: Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment","locator":"https://doi.org/10.2337/db25-749-p","provider":"crossref","retrievedAt":"2026-09-27T01:16:00.439Z","rawPayloadHash":"37356efe06444b201458870c4fd5cc57fe46ccd967fd7b998c8292e593f99b15"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:16:00.439Z","sourceUrl":"https://doi.org/10.2337/db25-749-p","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.180Z","updatedAt":"2026-09-27T02:32:11.180Z"},{"id":"8fd90a08-4cfc-4d6e-9853-095c65e3db15","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"778-P: Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model","sourceUrl":"https://doi.org/10.2337/db25-778-p","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.2337/db25-778-p","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.2337/db25-778-p","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:15:59.442Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5sf6006sfqe3yy1u1qts","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.2337/db25-778-p","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.2337/db25-778-p","pmid":null,"title":"778-P: Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model","locator":"https://doi.org/10.2337/db25-778-p","provider":"crossref","retrievedAt":"2026-09-27T01:15:59.441Z","rawPayloadHash":"779024de1683e0b704ed8d6f34cd97113be342f0912747ef7a753ca79dcd4d88"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:15:59.442Z","sourceUrl":"https://doi.org/10.2337/db25-778-p","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.040Z","updatedAt":"2026-09-27T02:32:11.040Z"},{"id":"b5e1e1c4-3f4b-4297-9334-0cdc4dc4f1b3","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators","sourceUrl":"https://doi.org/10.1161/circ.146.suppl_1.13440","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1161/circ.146.suppl_1.13440","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1161/circ.146.suppl_1.13440","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:04.924Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5vlm0073fqe3kjtnxb6n","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1161/circ.146.suppl_1.13440","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1161/circ.146.suppl_1.13440","pmid":null,"title":"Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators","locator":"https://doi.org/10.1161/circ.146.suppl_1.13440","provider":"crossref","retrievedAt":"2026-09-27T01:16:04.924Z","rawPayloadHash":"6af4fa8a6a3abd95822767b049e6e3ca7505f4884759b2666bbbb6c0fc3de9ee"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:16:04.924Z","sourceUrl":"https://doi.org/10.1161/circ.146.suppl_1.13440","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.743Z","updatedAt":"2026-09-27T02:32:11.743Z"},{"id":"c98ec9fe-f287-417d-bb9c-385e2518c43c","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials","sourceUrl":"https://doi.org/10.64898/2025.12.22.25342824","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.64898/2025.12.22.25342824","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.64898/2025.12.22.25342824","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:00.934Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5tb1006vfqe33ijj202j","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.64898/2025.12.22.25342824","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.64898/2025.12.22.25342824","pmid":null,"title":"Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials","locator":"https://doi.org/10.64898/2025.12.22.25342824","provider":"crossref","retrievedAt":"2026-09-27T01:16:00.934Z","rawPayloadHash":"60e0601e9e439f8ba2b3b71dcf82ddfc2ddfc5e6e8320a875e0bb1502e220b8c"}],"category":"confirmed_nonjournal_source","checkedAt":"2026-09-27T01:16:00.934Z","sourceUrl":"https://doi.org/10.64898/2025.12.22.25342824","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.250Z","updatedAt":"2026-09-27T02:32:11.250Z"},{"id":"71077ff2-f0d1-44fb-857b-7021486876b2","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"FRI-201 Effect of pemvidutide on cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis: 48-week results from the phase 2b, IMPACT trial","sourceUrl":"https://doi.org/10.1016/s0168-8278(26)01936-7","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1016/s0168-8278(26)01936-7","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1016/s0168-8278(26)01936-7","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:15:57.490Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5qph006mfqe3r3cmq0aq","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1016/s0168-8278(26)01936-7","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1016/s0168-8278(26)01936-7","pmid":null,"title":"FRI-201 Effect of pemvidutide on cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis: 48-week results from the phase 2b, IMPACT trial","locator":"https://doi.org/10.1016/s0168-8278(26)01936-7","provider":"crossref","retrievedAt":"2026-09-27T01:15:57.490Z","rawPayloadHash":"30122d8348a5905a9d26488c16ba5c483476c2696fa2eac51aa7a454dbe7df94"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:15:57.490Z","sourceUrl":"https://doi.org/10.1016/s0168-8278(26)01936-7","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:10.747Z","updatedAt":"2026-09-27T02:32:10.747Z"},{"id":"3ca08ab1-4b44-4f43-a5e5-e995f15bc066","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"LBP-036 Pemvidutide treatment led to fibrosis regression after 24 weeks in patients with metabolic dysfunction-associated steatohepatitis: quantitative digital pathology analysis from the IMPACT phase 2b, multicenter, randomized, placebo-controlled trial","sourceUrl":"https://doi.org/10.1016/s0168-8278(26)00451-4","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1016/s0168-8278(26)00451-4","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1016/s0168-8278(26)00451-4","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:15:56.450Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5q4o006kfqe3q3vmdb8v","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1016/s0168-8278(26)00451-4","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1016/s0168-8278(26)00451-4","pmid":null,"title":"LBP-036 Pemvidutide treatment led to fibrosis regression after 24 weeks in patients with metabolic dysfunction-associated steatohepatitis: quantitative digital pathology analysis from the IMPACT phase 2b, multicenter, randomized, placebo-controlled trial","locator":"https://doi.org/10.1016/s0168-8278(26)00451-4","provider":"crossref","retrievedAt":"2026-09-27T01:15:56.449Z","rawPayloadHash":"0199fc03d9d1706e036a8c24d2365b65d3737beec81b9bdb34c60d0e50417edc"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:15:56.450Z","sourceUrl":"https://doi.org/10.1016/s0168-8278(26)00451-4","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:10.531Z","updatedAt":"2026-09-27T02:32:10.531Z"},{"id":"4027ffb9-1b52-45fc-9f1c-5a517ebc619d","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"OS-016 Week 48 top-line results from the phase 2b, multicenter, randomized, placebo-controlled IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis","sourceUrl":"https://doi.org/10.1016/s0168-8278(26)00326-0","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1016/s0168-8278(26)00326-0","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1016/s0168-8278(26)00326-0","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:15:57.980Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5qzx006nfqe3iaya3n2i","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1016/s0168-8278(26)00326-0","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1016/s0168-8278(26)00326-0","pmid":null,"title":"OS-016 Week 48 top-line results from the phase 2b, multicenter, randomized, placebo-controlled IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis","locator":"https://doi.org/10.1016/s0168-8278(26)00326-0","provider":"crossref","retrievedAt":"2026-09-27T01:15:57.980Z","rawPayloadHash":"26737eed9100eea0a3d88ab2880e78e14907ab2631d9a87ef7621ef52c0ee082"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:15:57.980Z","sourceUrl":"https://doi.org/10.1016/s0168-8278(26)00326-0","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:10.817Z","updatedAt":"2026-09-27T02:32:10.817Z"},{"id":"a3300473-b565-4b50-afe9-442ebf497d4d","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial","sourceUrl":"https://doi.org/10.1016/s0168-8278(22)00570-0","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1016/s0168-8278(22)00570-0","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1016/s0168-8278(22)00570-0","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:05.432Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5vvw0074fqe3g7lu83mt","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1016/s0168-8278(22)00570-0","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1016/s0168-8278(22)00570-0","pmid":null,"title":"Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial","locator":"https://doi.org/10.1016/s0168-8278(22)00570-0","provider":"crossref","retrievedAt":"2026-09-27T01:16:05.432Z","rawPayloadHash":"f433fd5fb359c3747bbffab1a3551df1604c6986b07b7a7038e6e8ff7c24515d"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:16:05.432Z","sourceUrl":"https://doi.org/10.1016/s0168-8278(22)00570-0","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.813Z","updatedAt":"2026-09-27T02:32:11.813Z"},{"id":"7016886e-4b9e-4bc5-bc3c-16bd79b8e62b","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial","sourceUrl":"https://doi.org/10.1016/s0168-8278(23)00517-2","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1016/s0168-8278(23)00517-2","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1016/s0168-8278(23)00517-2","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:03.955Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5v0w0071fqe38vf39d3u","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1016/s0168-8278(23)00517-2","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1016/s0168-8278(23)00517-2","pmid":null,"title":"Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial","locator":"https://doi.org/10.1016/s0168-8278(23)00517-2","provider":"crossref","retrievedAt":"2026-09-27T01:16:03.954Z","rawPayloadHash":"eaf83eb00e635bddd988aa678bbd12f61236d847e5bba9af1ca123058778e924"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:16:03.955Z","sourceUrl":"https://doi.org/10.1016/s0168-8278(23)00517-2","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.603Z","updatedAt":"2026-09-27T02:32:11.603Z"},{"id":"8dd1478a-69ef-4493-96b1-a840c0256811","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"SAT-453 MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)","sourceUrl":"https://doi.org/10.1016/s0168-8278(25)01709-x","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1016/s0168-8278(25)01709-x","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1016/s0168-8278(25)01709-x","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:15:59.949Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5sq6006tfqe3nk4iya73","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1016/s0168-8278(25)01709-x","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1016/s0168-8278(25)01709-x","pmid":null,"title":"SAT-453 MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)","locator":"https://doi.org/10.1016/s0168-8278(25)01709-x","provider":"crossref","retrievedAt":"2026-09-27T01:15:59.948Z","rawPayloadHash":"496d73b83603f68c7d7db33c7892b7246ea5e924b86cbb2b1d03100f1200bf96"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:15:59.949Z","sourceUrl":"https://doi.org/10.1016/s0168-8278(25)01709-x","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.109Z","updatedAt":"2026-09-27T02:32:11.109Z"},{"id":"eeb641a0-2573-43e1-a186-373ef1f39ffc","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"TOP-176 Concurrent responses in multiple non-invasive tests for hepatic inflammation and fibrosis following pemvidutide treatment: 24-week responder analyses of the phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis","sourceUrl":"https://doi.org/10.1016/s0168-8278(26)01885-4","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1016/s0168-8278(26)01885-4","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1016/s0168-8278(26)01885-4","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:15:56.963Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5qf5006lfqe3xyw6d8ht","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1016/s0168-8278(26)01885-4","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1016/s0168-8278(26)01885-4","pmid":null,"title":"TOP-176 Concurrent responses in multiple non-invasive tests for hepatic inflammation and fibrosis following pemvidutide treatment: 24-week responder analyses of the phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis","locator":"https://doi.org/10.1016/s0168-8278(26)01885-4","provider":"crossref","retrievedAt":"2026-09-27T01:15:56.962Z","rawPayloadHash":"9e95bf3427c25e31231937711e52cbad2fd45b237f94f8d721cd1c9fae0f7b86"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:15:56.963Z","sourceUrl":"https://doi.org/10.1016/s0168-8278(26)01885-4","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:10.601Z","updatedAt":"2026-09-27T02:32:10.601Z"},{"id":"0a875d60-b5d4-45bb-8ce3-19efcdef5fcb","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial","sourceUrl":"https://doi.org/10.1016/s0168-8278(24)01555-1","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1016/s0168-8278(24)01555-1","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1016/s0168-8278(24)01555-1","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:02.456Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5u67006yfqe31d35sk52","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1016/s0168-8278(24)01555-1","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1016/s0168-8278(24)01555-1","pmid":null,"title":"WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial","locator":"https://doi.org/10.1016/s0168-8278(24)01555-1","provider":"crossref","retrievedAt":"2026-09-27T01:16:02.455Z","rawPayloadHash":"5bb8c9477c26a28ad56db43f42153b3934b2cad03a5dbddae813173a39f57ddc"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:16:02.456Z","sourceUrl":"https://doi.org/10.1016/s0168-8278(24)01555-1","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.460Z","updatedAt":"2026-09-27T02:32:11.460Z"},{"id":"2eaf78ff-58cd-4f15-baf6-278d3c6fa6c8","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"WED-219 Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model","sourceUrl":"https://doi.org/10.1016/s0168-8278(24)01560-5","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1016/s0168-8278(24)01560-5","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1016/s0168-8278(24)01560-5","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:01.425Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5tlb006wfqe3dkkzxqbn","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1016/s0168-8278(24)01560-5","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1016/s0168-8278(24)01560-5","pmid":null,"title":"WED-219 Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model","locator":"https://doi.org/10.1016/s0168-8278(24)01560-5","provider":"crossref","retrievedAt":"2026-09-27T01:16:01.425Z","rawPayloadHash":"ec16dce17df2b2aaf6c9a5c00c221548ac6abcad7ce55d899c7c7f7c5a278aae"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:16:01.425Z","sourceUrl":"https://doi.org/10.1016/s0168-8278(24)01560-5","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.320Z","updatedAt":"2026-09-27T02:32:11.320Z"},{"id":"efc80dc8-998f-4a98-8747-8cab2df2b845","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"WED-251 Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis","sourceUrl":"https://doi.org/10.1016/s0168-8278(24)01588-5","evidenceTier":"insufficient","summary":"Source reference associated with Pemvidutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.","authors":null,"publishingOrg":null,"publicationYear":null,"doi":"10.1016/s0168-8278(24)01588-5","pubmedId":null,"jurisdiction":null,"dateAccessed":null,"editorialNotes":null,"sourceType":"other","claimSupported":null,"supportNature":null,"qualification":"Bibliographic source verification only; this is not a scientific-conclusion approval.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"codex","reviewedById":null,"canonicalSourceIdentity":"doi:10.1016/s0168-8278(24)01588-5","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-27T01:16:03.449Z","retrievalProvider":"crossref","retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":{"scope":"source_identity_and_peptide_connection","decisionId":"cmudi5uqk0070fqe3lm0uzz7d","executedBy":"codex","candidateId":"directory-expansion:pemvidutide:10.1016/s0168-8278(24)01588-5","paidAiCalls":0,"authorizedBy":"owner","sourceAssessment":{"issues":[],"sources":[{"doi":"10.1016/s0168-8278(24)01588-5","pmid":null,"title":"WED-251 Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis","locator":"https://doi.org/10.1016/s0168-8278(24)01588-5","provider":"crossref","retrievedAt":"2026-09-27T01:16:03.449Z","rawPayloadHash":"b169c5c5a47e7211e9dc4381f2acb4e896ea099ee97760d8fc929b6d9ece6e4c"}],"category":"source_and_connection_confirmed","checkedAt":"2026-09-27T01:16:03.449Z","sourceUrl":"https://doi.org/10.1016/s0168-8278(24)01588-5","manualNote":null,"matchedNames":["pemvidutide","pemvidutide"]},"originalPeptideSlug":"pemvidutide","canonicalPeptideSlug":"pemvidutide","fullScientificValidation":false,"personalOwnerReviewPerformed":false},"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-27T02:32:11.532Z","updatedAt":"2026-09-27T02:32:11.532Z"},{"id":"4556b796-4ef4-4f22-9570-580d3e240157","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41879841/","evidenceTier":"insufficient","summary":"Content-verified record concerning Pemvidutide: \"Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.\" Abstract excerpt: Metabolic dysfunction-associated steatohepatitis (MASH) contributes substantially to liver and cardiometabolic disease. Pemvidutide, a dual GLP-1/glucagon receptor agonist, may provide combined hepatic and systemic benefits. We conducted a meta-analysis of randomized controlled trials comparing pemvidutide versus placebo in adults with MASLD/MASH. Data were pooled using random-effects models to es","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1007/s00210-026-05257-1","pubmedId":"41879841","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: systematic review or meta-analysis. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=120, totalMentions=4). Imported evidence lane: synthesis. Source provider: WPF seed. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"systematic_review_or_meta_analysis","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s00210-026-05257-1","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.497Z","updatedAt":"2026-09-23T23:29:34.093Z"},{"id":"a6848a84-302a-4234-b094-1ff398ccbf53","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/39002641/","evidenceTier":"animal","summary":"Randomized study in MASLD; endpoint and follow-up require full-text appraisal.","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1016/j.jhep.2024.07.006","pubmedId":"39002641","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Upgraded from an entered/unverified draft to a content-verified citation. Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=87, totalMentions=7). Imported evidence lane: preclinical_animal. Source provider: WPF seed. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":"This publication addresses Pemvidutide in the specific setting identified in its title.","supportNature":"Screened source-level context; specific outcomes and evidence tier await appraisal.","qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.jhep.2024.07.006","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T02:13:10.585Z","updatedAt":"2026-09-23T23:29:34.093Z"},{"id":"a5e61daf-d194-4934-b54e-b20a1443d677","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41113119/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Pemvidutide: \"Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.\" Abstract excerpt: This was a double-blind 12-week extension of a randomized, placebo-controlled, 12-week trial of pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Completers of a double-blind trial of pemvidutide in MASLD, who were previously randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or ","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1016/j.jhepr.2025.101483","pubmedId":"41113119","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=96, totalMentions=9). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.jhepr.2025.101483","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.689Z","updatedAt":"2026-09-23T23:29:34.093Z"},{"id":"6fc8b854-309f-44f3-ad66-f3620f8044b4","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41237796/","evidenceTier":"animal","summary":"Content-verified record concerning Pemvidutide: \"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.\" Abstract excerpt: GLP-1-glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of this trial was to assess the effects of pemvidutide on MASH resolution and fibrosis improvement in patients with liver fibrosis stage F2 or F3 MASH at 24 weeks of treatment. IMPACT is an ongoing 48-week international, randomised, double-blind,","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1016/S0140-6736(25)02114-2","pubmedId":"41237796","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=46, totalMentions=13). Imported evidence lane: preclinical_animal. Source provider: WPF seed. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(25)02114-2","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.616Z","updatedAt":"2026-09-23T23:29:34.093Z"},{"id":"913d7425-6f7c-4e1a-a2e5-b4b0da980a40","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","title":"The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41352959/","evidenceTier":"insufficient","summary":"Content-verified record concerning Pemvidutide: \"The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.\" (identity confirmed; no abstract text available to excerpt.)","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1016/s0140-6736(25)02304-9","pubmedId":"41352959","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: Read directly: title and known trial identity confirm a primary pemvidutide phase 2b report; not yet MEDLINE-indexed.. Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s0140-6736(25)02304-9","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T23:11:35.223Z","updatedAt":"2026-09-23T23:29:34.093Z"}],"regulatory":[{"id":"e81499ee-f1da-4570-beaa-78087a433012","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","jurisdiction":"European Union — EMA","status":"not_approved","approvedIndication":null,"rationale":"No centrally authorized EMA medicine containing pemvidutide was identified in the EMA medicines database as of 2026-09-23. Pemvidutide remains investigational with no completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific.","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","dateChecked":"2026-09-23T00:00:00.000Z","reviewDueAt":"2026-12-22T00:00:00.000Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-23T02:42:18.950Z","updatedAt":"2026-09-23T23:29:34.166Z"},{"id":"368e5069-d525-46ce-bb1f-51374694020d","peptideId":"779c2af5-3a80-4717-b50e-ee2c4c9669b0","jurisdiction":"United States — FDA","status":"not_approved","approvedIndication":null,"rationale":"No FDA-approved product containing pemvidutide was identified in the FDA Drugs@FDA database as of 2026-09-23. Pemvidutide (ALT-801) remains an investigational compound in clinical development, with no completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific.","sourceTitle":"FDA Drugs@FDA database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","dateChecked":"2026-09-23T00:00:00.000Z","reviewDueAt":"2026-12-22T00:00:00.000Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-23T02:42:18.875Z","updatedAt":"2026-09-23T23:29:34.166Z"}],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}